News

Scotland: £60m for genomic medicine
Enlarge image

FundingUK

Scotland: £60m for genomic medicine

29.08.2012 - A pioneering genetics research centre at the University of Edinburgh receives £60m (€75,6m) funding from the Medical Research Council (MRC).

The university has also received a £3.5m (€4,4m) award from the Wellcome Trust and Wolfson Foundation to help fund the building of a new systems medicine centre. The MRC funding will be used to fund research at Edinburgh's MRC Human Genetics Unit and the MRC Institute of Genetics and Medicine (IGMM) into a range of conditions, such as schizophrenia, cystic fibrosis, and genetic eye disorders, and to develop and test new therapies. IGMM is a partnership between the MRC, the University of Edinburgh's Centre for Molecular Medicine, and Cancer Research UK.

“This funding will help us to turn the potential of the genetic revolution into reality” said Institute director Nick Hastie in a video. He explained that most of the money would continue to fund ongoing programmes in the Human Genetics Unit, but that “ten to twenty percent, combined with money from the University of Edinburgh, will allow us to do exciting new science”. This would include recruiting top researchers, purchasing new equipment, developing a brand new PhD programme and helping the centre to integrate its research with the NHS. Professor Hastie said that the ‘big aim’ was to bring the results of research into clinical practice to aid the diagnosis and treatment of disease.

The £3.5m in funding from the Wellcome Trust and the Wolfson Foundation, awarded under the Wellcome-Wolfson Capital Awards programme, will support a new systems medicine building with the construction set to start in 2013 at Edinburgh's Western General Hospital. The five-story systems medicine building will total 2,700 meters squared, and will "create a physical and intellectual bridge between centres that make up the IGMM. In addition to research spaces, the facility will include spaces for computational biology, a seminar room, offices, and an "open design" to encourage research collaborations, according to IGMM. The remainder of the estimated £10.2m for the systems medicine facility will be provided by the University of Edinburgh and the MRC.

http://www.european-biotechnology-news.com/news/news/2012-03/scotland-pound60m-for-genomic-medicine.html

Stock MarketsFranceEU

27.03.2015 Europe is once more proving that it can be a good bet for biotech companies going public. A newly established EU-wide lobbying initiative could help the IPO boom on its way.

FinancingPoland

24.03.2015 Poland has announced the closing of a new venture capital fund at US$42m (€32m). The fund, which is the first of its kind in Poland, is dedicated to the Life Sciences with a strong connection to Central and Eastern Europe.

BioeconomyFranceSwedenGermanyNetherlandsFinland

23.03.2015 A BASF-led consortium aims to decrease bio-based production costs using industrial biotechnology. The Horizon2020 funded consortium is the sixth project of the SPIRE Public Private Partnership and has a budget of €14m.

Stock MarketsFranceSwedenUKNorwayIreland

20.03.2015 There are no signs of inertia creeping into the European biotech industry this spring. A total of eight IPOs are set to go public by the end of the year’s first quarter.

FinancingUKEU

17.03.2015 Pharma giants GlaxoSmithKline (GSK) and Johnson & Johnson (J&J) will be key collaborators in a new global fund for dementia research to address the rising threat posed by dementia and Alzheimer’s disease.

FinancingFranceDenmarkSwedenGermany

19.03.2015 French venture capital firm Seventure Partners has raised a further €25m for its microbiome-focused Health for Life Capital Fund. It now stands at €100m.

EventsFranceEUSwitzerlandUKGermany

12.03.2015 With around 1,400 companies and 2,400 participants, the springtime counterpart of BIO-Europe enjoyed a successful premiere in France this year. The overall mood of the European biotech industry was positive, and the French hosts in particular reported new initiatives.

M&ABelgium

11.03.2015 Belgian cell-based therapeutics developer and CMO MaSTherCell SA has been acquired by US biotech Orgenesis Inc. for €23m.

FinancingGermany

10.03.2015 The Gates Foundation has dipped into its purse to bring infectious diseases vaccines to the poorest countries. German vaccine specialist CureVac is set to receive US$52m for their mRNA platform technology.

Stock MarketsIrelandUK

05.03.2015 The IPO wave in the biotech sector shows no signs of slowing down. An Irish life sciences fund set up by former Elan executives plans to raise €325m with its IPO, whilst Summit Therapeutics has announced its IPO pricing of US$34m on Nasdaq.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • THERAMETRICS0.09 CHF12.50%
  • FORMYCON24.58 EUR6.18%
  • CYTOS1.45 CHF3.57%

FLOP

  • MEDIGENE10.52 EUR-9.70%
  • BIOFRONTERA2.53 EUR-3.44%
  • 4SC1.25 EUR-2.34%

TOP

  • CYTOS1.45 CHF326.5%
  • MEDIGENE10.52 EUR147.5%
  • 4SC1.25 EUR60.3%

FLOP

  • MORPHOSYS56.55 EUR-24.4%
  • WILEX3.00 EUR-12.5%
  • BASILEA108.00 CHF-11.6%

TOP

  • SANTHERA92.40 CHF2269.2%
  • WILEX3.00 EUR400.0%
  • FORMYCON24.58 EUR251.1%

FLOP

  • CYTOS1.45 CHF-51.3%
  • MOLOGEN5.81 EUR-48.7%
  • PAION2.34 EUR-29.9%

No liability assumed, Date: 29.03.2015